FDA: Label changes for finasteride expand list of adverse eventsApril 25th 2012
The FDA has announced changes to the professional labels for finasteride, 5 mg (Proscar), and finasteride, 1 mg (Propecia), to expand the list of sexual adverse events reported to the FDA, as some of these events have been reported to continue after the drug is no longer being used.
Drug maker unblinds phase III study of advanced prostate Ca therapyMarch 21st 2012
Janssen Research & Development, LLC, recently has unblinded the phase III study of the androgen biosynthesis inhibitor abiraterone acetate (ZYTIGA) plus prednisone for the treatment of asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) who have not received chemotherapy.
5-ARI with T supplementation does not affect muscle mass, strengthMarch 14th 2012
Men receiving testosterone supplementation who also receive the 5-alpha-reductase inhibitor dutasteride (Avodart) do not experience a significant difference in changes in muscle mass, muscle strength, or sexual function compared with men who do not receive dutasteride, according to a recent study.
Investigational OAB agent demonstrates efficacy, tolerabilityMarch 7th 2012
Results from three separate clinical trials further support the efficacy and tolerability of the investigational beta3-adrenoceptor agonist mirabegron for the treatment of OAB, researchers reported at the 2012 European Association of Urology annual congress in Paris.
FDA panel votes against wider use of RANK ligand inhibitor in PCa patientsFebruary 23rd 2012
An FDA advisory panel recommended against using the RANK ligand inhibitor denosumab (XGEVA) to delay or prevent the spread of castration-resistant prostate cancer in patients at high risk for bone metastases.
BPH scores improved by PDE-5 inhibitor, alpha-blockerFebruary 23rd 2012
Both the phosphodiesterase-type-5 inhibitor tadalafil (Cialis) and alpha-blocker tamsulosin (Flomax) appear to significantly improve scores on the International Prostate Symptom Score (IPSS) compared with placebo in men with signs and symptoms suggestive of BPH.
Targeted kidney cancer drugs may raise risk of fatal side effectsFebruary 15th 2012
Treatment with three relatively new targeted kidney cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute, Boston.
Cephalosporin antibiotic inferior to ciprofloxacin for cystitisFebruary 15th 2012
Short-term use of the cephalosporin antibiotic cefpodoxime proxetil (Vantin) for the treatment of women with uncomplicated cystitis did not meet criteria for noninferiority for achieving clinical cure compared with ciprofloxacin (Cipro, Proquin), say researchers from the University of Miami Miller School of Medicine.
5-ARI delays prostate cancer progression in men with low-risk diseaseFebruary 8th 2012
The 5-alpha-reductase inhibitor dutasteride (Avodart) appears to delay disease progression and the initiation of active treatment in men with low-risk, localized prostate cancer, results of a 3-year international clinical trial indicate.
Denosumab results in less pain interference, according to studyJanuary 1st 2012
Pain interference with daily functioning was significantly less in men with castrate-resistant prostate cancer who were treated with the RANK ligand inhibitor denosumab (XGEVA) compared to zoledronic acid (Zometa) as part of a multinational, double-blind, randomized trial.
Investigational treatment improves survival in metastatic prostate cancerDecember 1st 2011
In men with castration-resistant prostate cancer and symptomatic bone metastases, the investigational radiopharmaceutical radium-223 (Alpharadin) improved overall survival by 30% and time to first skeletal-related event by 39% compared with placebo.
CMS now covering prostate Ca immunotherapy infusion costsDecember 1st 2011
Dendreon Corp. has announced that the Centers for Medicare & Medicaid Services has updated its coverage policy to now cover the infusion costs associated with the administration of the advanced prostate cancer immunotherapy sipuleucel-T (Provenge).
RANK ligand inhibitor delays development of PCa bone metastasisDecember 1st 2011
Treatment with the RANK ligand inhibitor denosumab (XGEVA) is effective at delaying the development of bone metastases in men with nonmetastatic castration-resistant prostate cancer, according to a recent multicenter study.
Achilles' heel in lethal prostate cancer discoveredDecember 1st 2011
An international research team has discovered a genetic Achilles' heel in neuroendocrine prostate cancer-a vulnerability that researchers say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.
PDE-5 inhibitor approved to treat men with both BPH and EDOctober 20th 2011
Eli Lilly and Co. has announced that the FDA has approved the phosphodiesterase type-5 inhibitor tadalafil (Cialis) for once-daily use for the treatment of men who have both erectile dysfunction and the signs and symptoms of BPH.
Bisphosphonate offers prostate Ca pain reliefOctober 13th 2011
A single dose of a bisphosphonate in prostate cancer patients with bone metastases is as effective for pain relief as single-dose radiotherapy, according to a study presented at the European Multidisciplinary Cancer Congress in Stockholm, Sweden.
Investigational PCa agent improves survival in patients with bone metsOctober 13th 2011
An investigational alpha-pharmaceutical appears to significantly prolong survival in patients with bone metastases from advanced prostate cancer, British researchers reported at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden.
Company submits new drug application for OAB therapySeptember 15th 2011
Astellas Pharma Inc. has announced the submission of a new drug application and market authorization application for mirabegron, a once-daily oral selective beta3-adrenoceptor agonist, to the FDA and the European Medicines Agency.
Advanced prostate Ca treatment shows long-term efficacySeptember 15th 2011
Long-term use of degarelix (Firmagon), a gonadotropin-releasing hormone therapy approved for the treatment of advanced prostate cancer in both Europe and the United States, continues to be effective and well tolerated beyond 3 years, according a recent study.
Canadian agency: 5-ARI may be linked to male breast cancer riskAugust 25th 2011
Health Canada is informing health care practitioners and patients of a labeling update for the 5-alpha-reductase inhibitor finasteride (Propecia, Proscar) to add safety information regarding rare reports of breast cancer in men.